Health news summaries — Page 3
Essential facts and source links for recent health stories.
-
CUE-221 trial finds full hive resolution in 54% on highest dose
Cue Biopharma said its Phase 2 trial in China found complete resolution of chronic hives at week 12 in 54% of patients given CUE-221 at 4 mg/kg, versus 11% on placebo. The 145-patient study met its primary endpoint; its week-28 omalizumab comparison was post hoc. -
Eurocontrol freezes Polish, Romanian air-fee transfers as Pfizer enforces €1.9bn judgment
Pfizer is enforcing a Belgian judgment requiring Poland and Romania to pay €1.9 billion for vaccine doses they declined under a 2021 EU contract. Eurocontrol has frozen route-fee transfers to their aviation agencies as both countries challenge enforcement. -
Roughly half of New York home care is under private-equity control
Cornell’s Worker Institute says private equity controls roughly half of New York’s home-care market, now consolidated and highly leveraged. PE-backed agencies collected more than $2.32 billion in Medicaid payments in 2022; debt service takes funds from care and wages. -
Apple plans iOS 27 Health revamp with readiness scores and Watch sensors
Apple plans an iOS 27 Health app redesign with Apple Intelligence guidance and a daily 0–10 readiness score combining activity, sleep and vital signs, the Wall Street Journal reported. The report also links it to upgraded sensors in Apple Watch Series 12 and Ultra 4. -
After three deaths, Novartis pauses eight CAR-T trials; Bristol Myers pauses new enrollment
Novartis paused eight autoimmune and neurological rap-cel CAR-T trials after three patients died from a rare, severe immune reaction. Bristol Myers paused new enrollment in zola-cel trials after events it called transient and reversible; it reported no deaths. -
Novartis investor seeks board shake-up over acquisition oversight
Artisan Partners, one of Novartis’ 20 largest shareholders, called for a board shake-up to improve acquisition oversight after two trial failures preceded an 11% one-day drop, erasing nearly $30 billion in market value and the stock’s 2026 gains. -
Motley Fool sees more upside in AbbVie than J&J for 2026
The Motley Fool sees greater upside in AbbVie, citing its 18.8x forward P/E and pipeline, compared with Johnson & Johnson’s 23.5x. J&J posted the higher FY2025 net margin; AbbVie faces patent and revenue-concentration risks, while J&J faces talc litigation. -
Elysium launches TELI as a telehealth program for longevity care
Elysium Health launched TELI Sept. 9, an online longevity-care program where licensed providers assess eligible adults and create personalized plans when clinically appropriate. Its 18 protocols cover prescription drugs, peptides, supplements and vitamins. -
Gias Foods recalls two lots of Walmart’s bettergoods fettuccine over possible Listeria
Gias Foods recalled two lots of Walmart’s bettergoods Authentic Italian Lemon Alfredo Fettuccine after state testing indicated they may contain Listeria. The bags were sold nationwide, and the company says no illnesses have been reported to date. -
Alice Walton’s net worth rose $33 billion; her medical school has 96 students
Alice Walton’s net worth rose $33 billion from March 2025 to March 2026, according to Forbes data cited by Fortune. Her Arkansas medical school has 96 students and waives tuition for its first five graduating classes; students pay fees and living costs. -
Buffalo fund says confidence in Corcept's execution and pipeline aided shares
In its Q2 2026 letter, Buffalo Mid Cap Discovery Fund said Corcept Therapeutics added to its relative performance, with the stock benefiting from improved investor confidence in the company’s commercial execution and pipeline opportunities. -
Experts say workplace stress needs more than coping apps
Gallup's survey of more than 141,000 employed adults across 140-plus countries found 40% had experienced stress the previous day, rising to 50% in the US and Canada. Experts say coping apps may help, but employers also need to address harmful workloads and workplace conditions. -
Pennsylvania Reddit example illustrates income’s role in pre-65 insurance costs
A Pennsylvania Reddit commenter cited 2026 estimates for a married couple’s cheapest ACA Silver plan: $3,672 at $35,000 MAGI, $4,908 at $45,000 and $30,660 at $100,000. The example illustrates how income can affect coverage costs before Medicare eligibility at 65. -
Ashland’s Permexa launch comes amid Life Sciences growth and wider EBITDA decline
Ashland launched Permexa sodium caprate on Aug. 24 to help drugmakers make oral versions of injectable peptides and biologics; no product revenue figure has been disclosed. Q3 Life Sciences sales rose 11% to $180 million, while companywide adjusted EBITDA fell 4% to $109 million. -
ACADIA shares drop 12.78% after remlifanserin trial misses Phase 2 goal
ACADIA Pharmaceuticals fell 12.78% to $22.18 on Thursday after Goldman Sachs reiterated its sell rating and $17 price target, citing remlifanserin’s failure to meet the primary endpoint in a Phase 2 trial for Alzheimer’s disease psychosis. -
Royalty Pharma offers RASONQUE exposure through a broader drug portfolio
After the FDA gave Revolution Medicines’ RASONQUE, a metastatic pancreatic cancer drug, breakthrough therapy designation, Motley Fool argues Royalty Pharma offers exposure to it alongside investments in 35 approved products and 17 drugs in development. -
Merck’s sac-TMT trial results due Oct. 25 as BofA retains Buy rating
Bank of America kept its Buy rating and $166 target for Merck, citing pipeline data expected over the next 12–18 months. A trial found sac-TMT plus Keytruda delayed progression versus chemotherapy plus Keytruda in first-line lung cancer; full results are due Oct. 25. -
Wakefern recalls Wholesome Pantry applesauce after FDA detects excess patulin
Wakefern recalls 23-ounce jars of Wholesome Pantry Organic Unsweetened Apple Sauce after FDA monitoring found patulin above acceptable limits. They bear UPC 04119005677 and a June 16, 2027 best-by date; no linked illnesses or injuries have been reported. -
RYBREVANT’s final PAPILLON survival result wasn’t statistically significant
Patients with advanced lung cancer carrying EGFR exon 20 insertions had median overall survival of 34.3 months with J&J’s RYBREVANT plus chemotherapy in PAPILLON, versus 27.9 months with chemotherapy alone; the final analysis was not statistically significant. -
Berenberg upgrades GSK and raises target to 2,200p on pipeline momentum
Berenberg upgraded GSK to Buy from Hold on Sept. 15 and raised its price target to 2,200p from 2,000p, citing pipeline momentum. That day, GSK agreed to acquire global rights to Chimagen’s trispecific T-cell engager for multiple myeloma in a deal worth up to $750 million. -
Contineum’s PIPE-307 misses Phase 2 depression trial’s primary endpoint
Contineum-developed JNJ-5120/PIPE-307 missed the primary efficacy endpoint in a Phase 2 study of 107 adults with major depression. Contineum said the drug was well tolerated, with no new safety signals; J&J is reviewing data before deciding next steps. -
GSK to acquire global rights to Chimagen myeloma drug for up to $750 million
GSK agreed to acquire full global rights to Chimagen Biosciences’ experimental trispecific T-cell engager for multiple myeloma in a deal worth up to $750 million. The drug has not entered human trials; GSK expects Phase I testing to begin in 2027. -
AstraZeneca's camizestrant misses primary endpoint in SERENA-4 trial
AstraZeneca said Phase III SERENA-4 missed its primary endpoint: camizestrant plus palbociclib did not significantly improve progression-free survival over anastrozole plus palbociclib in first-line ER-positive, HER2-negative advanced breast cancer. -
Apollo reportedly in talks to buy J&J’s DePuy Synthes for nearly $20 billion
Bloomberg reported Sept. 11 that Apollo Global Management is in talks to buy Johnson & Johnson’s DePuy Synthes orthopedics unit for close to $20 billion. The business generated $9.3 billion in 2025 revenue; J&J had announced plans to separate it within 18 to 24 months. -
Six breakfast staples may fit a healthy diet, dietitians say
Six familiar breakfast foods, including eggs, smoothies and pancakes, can fit a healthy diet, dietitians say, depending on ingredients and preparation. They favor whole grains, produce, fiber and protein, with less added sugar, saturated fat and sodium. -
Novo Nordisk shares fall nearly 8% after CEO discusses semaglutide patent risk
Novo Nordisk's American depositary shares fell nearly 8% after CEO Mike Doustdar addressed semaglutide's loss-of-exclusivity risk at a London investor day. Its U.S. patent expires in 2032, and Wegovy and Ozempic account for about 75% of revenue.
